I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional in Switzerland

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home Oncology Foundation Medicine

Foundation Medicine

What's new

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Apr 8 / Roche and Genentech
Conceptualization of core clinico-molecular variables for registries enrolling patients diagnosed with a solid tumor and profiled with next-generation sequencing (NGS)
This study proposes a framework for identifying the core variables that are most critical for solid tumor-based, real-world studies and registries in precision oncology. Mandatory and optional variables are described, as well as recommendations for vocabularies to use, which will provide viable guidance for conducting research- and regulatory-grade real-world precision oncology studies, and facilitating standardized data collection and thus pooling from various datasets.
Oncology Foundation Medicine Real World Data - Real World Evidence AACR-2022

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Apr 8 / Roche and Genentech
WAYFIND-R: Delivering a high-quality real-world data (RWD) global registry of patients diagnosed with a solid tumor and profiled with next-generation sequencing (NGS)
This poster presents the study design of WAYFIND-R, a global, prospective, longitudinal, and generalizable registry of adults with any type/stage of solid tumor profiled with next-generation sequencing (NGS) ≤3 months before enrollment. WAYFIND-R will inform on best practice for NGS-based treatment decisions by clinicians, foster global collaborations between cancer centers (enabling robust conclusions to be drawn regarding outcome data), aid understanding of disparities in patients’ access to advanced diagnostics and therapies, and ultimately drive advances in precision oncology.
Oncology Foundation Medicine Real World Data - Real World Evidence AACR-2022

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Sep 16 / Roche and Genentech
Supplementary data: Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)
This study used structured and unstructured data from the US nationwide electronic health record-derived de-identified Flatiron Health database to describe the utilisation and predictors of RAS, BRAF and microsatellite instability testing (both next-generation sequencing and non-next-generation sequencing), prior to first-line therapy initiation in stage IV or recurrent metastatic colorectal cancer (between 2013 and 2020).
Oncology Foundation Medicine Real World Data - Real World Evidence ESMO-2021

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Sep 16 / Roche and Genentech
Utilisation and predictors of genomic testing prior to first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC)
This study used structured and unstructured data from the US nationwide electronic health record-derived de-identified Flatiron Health database to describe the utilisation and predictors of RAS, BRAF and microsatellite instability testing (both next-generation sequencing and non-next-generation sequencing), prior to first-line therapy initiation in stage IV or recurrent metastatic colorectal cancer (between 2013 and 2020).
Oncology Foundation Medicine Real World Data - Real World Evidence ESMO-2021

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Sep 16 / Roche and Genentech
Supplementary data: Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO
This study was a preliminary, descriptive molecular analysis of ~50% of patients designated for enrolment in CUPISCO (NCT03498521), an ongoing, phase II randomised study of targeted therapy/cancer immunotherapy vs platinum-based chemotherapy in patients with unfavourable carcinoma-of-unknown-primary-origin (per European Society for Medical Oncology guidelines). The study utilised comprehensive genomic profiling to analyse gene alterations occurring in ≥3% of patients, using multiple correspondence analyses and hierarchical clustering to identify co-occurrences. The genomic signatures microsatellite instability and tumour mutational burden were also determined.
Oncology Foundation Medicine Comprehensive Genomic Profiling ESMO-2021

Sign up or login to unlock the full suite of MEDICALLY features
Personalised Healthcare
Sep 16 / Roche and Genentech
Baseline mutational profiles of patients (pts) with carcinoma-of-unknown-primary-origin (CUP) enrolled onto CUPISCO
This study was a preliminary, descriptive molecular analysis of ~50% of patients designated for enrolment in CUPISCO (NCT03498521), an ongoing, phase II randomised study of targeted therapy/cancer immunotherapy vs platinum-based chemotherapy in patients with unfavourable carcinoma-of-unknown-primary-origin (per European Society for Medical Oncology guidelines). The study utilised comprehensive genomic profiling to analyse gene alterations occurring in ≥3% of patients, using multiple correspondence analyses and hierarchical clustering to identify co-occurrences. The genomic signatures microsatellite instability and tumour mutational burden were also determined.
Oncology Foundation Medicine Comprehensive Genomic Profiling ESMO-2021

Ask a question or share feedback

Get in touch

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.